No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

First Nation Group and NightWare Partner to Deliver First and Only Therapeutic Platform Designed and FDA Cleared to Treat Nightmares Related to PTSD

Editor: What To Know

  • Using machine learning, NightWare creates a Smart Sleep Stress Index™ of a person's sleep to detect a nightmare and intervene to disrupt the nightmare resulting in improved sleep.
  • Today First Nation Group announced a new partnership with NightWare, the creators of the NightWareTM therapeutic platform, to deliver innovative care to our nation's heroes diagnosed and struggling with severe nightmares associated with post-traumatic stress disorder (PTSD) or nightmare disorder.
  • The expansion of Sleep Therapy solutions to include the PTSD and nightmare disorder products, allows First Nation Group to meet the needs of Veterans and active duty military personnel suffering from clinically significant nightmares.

December 10, 2020

First Nation Group offers NightWare™, a digital therapeutic platform delivered through the Apple Watch® to interrupt PTSD-related nightmares, to Government customers.

Today First Nation Group announced a new partnership with NightWare, the creators of the NightWareTM therapeutic platform, to deliver innovative care to our nation’s heroes diagnosed and struggling with severe nightmares associated with post-traumatic stress disorder (PTSD) or nightmare disorder.

NightWare is a digital therapeutic platform using artificial intelligence to create a personalized treatment for patients suffering from nightmares. It delivers the therapy through the Apple Watch to improve sleep disturbance. This partnership allows U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), and other federal agencies to provide life-changing therapy to impact PTSD-associated nightmares in adults.

“We are proud to be able to bring a non-pharmacological therapy to market to assist Veterans suffering from PTSD-associated nightmares,” said Glenn Munroe, Senior Vice President of Business Development for First Nation Group. “We believe NightWare will allow those struggling with nightmare disorder to experience restorative sleep on a nightly basis.”

NightWare is an FDA cleared medical device that uses sensors on the watch to monitor an adult patient’s sleep. Using machine learning, NightWare creates a Smart Sleep Stress Index™ of a person’s sleep to detect a nightmare and intervene to disrupt the nightmare resulting in improved sleep. In their ongoing randomized and controlled clinical trial, NightWaresaw improved sleep disturbance over control in Veterans diagnosed with PTSD and nightmare disorder. There were no adverse events reported during the study. The trial is ongoing.

“NightWare is excited to market our first-of-its-kind treatment for nightmare disorder with First Nation Group,” said Grady Hannah, Chief Executive Officer of NightWare. “First Nation Group is the premier medical-surgical distributor for Sleep Therapy in the VA and the DoD. This is a mission-driven organization with a passion for helping Veterans and it shows.”

First Nation Group, the premier Service-Disabled Veteran-Owned Small Business, Women-Owned Small Business, and HUBZone Small Business medical-surgical distributor, has served the Federal Government since 1992. The expansion of Sleep Therapy solutions to include the PTSD and nightmare disorder products, allows First Nation Group to meet the needs of Veterans and active duty military personnel suffering from clinically significant nightmares.

“Every Veteran that has served this nation with honor and dedication should be able to end each day with a restful night’s sleep,” said Cheryl Nilsson, Owner and Chief Executive Officer of First Nation Group. “We are proud to partner with NightWare to provide Veterans and active duty service members suffering from PTSD with more innovative, non-invasive treatment options to improve mental and physical health, starting with a good night’s sleep.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy